Trial intelligence / Profile preview

DMARD tapering versus usual care in rheumatoid arthritis and psoriatic arthritis

ACTRN12621001695897Phase 4Recruiting

Sponsor: University of Sydney
Start: Dec 2022
Modality: Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, randomised, open-label trial of adalimumab, etanercept, infliximab, golimumab, certolizumab pegol and 13 more in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (5 arms), sponsored by University of Sydney. Primary endpoints: Maintenance of low disease activity/minimal disease activity without taper failure and Cost per quality-adjusted life year. Started Dec 2022; status: recruiting.

Drugs

adalimumabetanerceptinfliximabgolimumabcertolizumab pegol

Conditions

rheumatoid arthritis (RA)psoriatic arthritis (PsA)

Beyond the preview

Go deeper on ACTRN12621001695897.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ACTRN12621001695897.